PUBLIC COMPANY
save$KURAKura Oncology, Inc.
$KURA9.9400+0.10%San Diego, CA, USupdated 5h ago
community read0 votes
pipeline
3
marketed
1
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 11Phase 31Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →Active trials
- phase3Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- phase2First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- phase1KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- phase1Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- phase1A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- phase1A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- phase2Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
- —Expanded Access to Ziftomenib
Insider activity
source: SEC Form 4routine RSU / option mechanics (4)
- Mar 23, 26option exerciseWILSON TROY EDWARD · President and CEO6,103 sh
- Mar 23, 26option exerciseWILSON TROY EDWARD · President and CEO6,103 sh
- Mar 18, 26option exerciseMalley Thomas · director10,000 sh
- Mar 18, 26option exerciseMalley Thomas · director10,000 sh
🐶 Hiring Signal
News
- AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as WavePlus news about Kailera, Alfasigma, Junshi and Kura. ⏰ FDA delays AstraZeneca’s camizestrant PDUFA date: The FDA has extended its PDUFA date for AstraZeneca’s breast cancer drug camizestrant, a few…endpoints · 2mo ago
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that